Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- Check6 days agoChange DetectedRecruitment status now indicates no participant enrollment; new sections for How to Read a Study Record, Common Questions, and How to Join a Study were added, and the Intervention/Treatment heading was adjusted with a revision note updated to v3.6.0.SummaryDifference0.4%

- Check13 days agoChange DetectedThe page's revision label updates from v3.5.4 to v3.5.5, indicating a new build/version of the page. This is a minor metadata change that does not alter visible content or functionality.SummaryDifference0.0%

- Check20 days agoChange DetectedSponsor attribution and the credits label are removed from the study page, altering how the page credits its sponsor and provides external links.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This represents a small metadata update indicating a new publication revision.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page’s footer revision/version number has been updated from v3.5.2 to v3.5.3, indicating a site release or template update without substantive changes to the clinical trial information.SummaryDifference0.0%

- Check63 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.